Nanoviricides Inc (NNVC)
2.40
-0.03
(-1.23%)
USD |
NYAM |
May 31, 16:00
2.40
0.00 (0.00%)
After-Hours: 20:00
Nanoviricides Research and Development Expense (TTM): 7.168M for March 31, 2024
Research and Development Expense (TTM) Chart
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| March 31, 2024 | 7.168M |
| December 31, 2023 | 7.150M |
| September 30, 2023 | 6.746M |
| June 30, 2023 | 6.392M |
| March 31, 2023 | 4.651M |
| December 31, 2022 | 4.71M |
| September 30, 2022 | 4.801M |
| June 30, 2022 | 5.785M |
| March 31, 2022 | 6.197M |
| December 31, 2021 | 6.406M |
| September 30, 2021 | 6.638M |
| June 30, 2021 | 6.114M |
| March 31, 2021 | 5.597M |
| December 31, 2020 | 5.267M |
| September 30, 2020 | 4.786M |
| June 30, 2020 | 4.696M |
| March 31, 2020 | 5.215M |
| December 31, 2019 | 5.391M |
| September 30, 2019 | 6.037M |
| June 30, 2019 | 5.966M |
| March 31, 2019 | 5.910M |
| December 31, 2018 | 5.892M |
| September 30, 2018 | 5.873M |
| June 30, 2018 | 5.914M |
| March 31, 2018 | 6.676M |
| Date | Value |
|---|---|
| December 31, 2017 | 6.944M |
| September 30, 2017 | 6.566M |
| June 30, 2017 | 6.566M |
| March 31, 2017 | 5.874M |
| December 31, 2016 | 5.382M |
| September 30, 2016 | 5.274M |
| June 30, 2016 | 5.104M |
| March 31, 2016 | 4.888M |
| December 31, 2015 | 4.367M |
| September 30, 2015 | 4.131M |
| June 30, 2015 | 3.660M |
| March 31, 2015 | 4.475M |
| December 31, 2014 | 4.555M |
| September 30, 2014 | 4.768M |
| June 30, 2014 | 5.132M |
| March 31, 2014 | 3.944M |
| December 31, 2013 | 4.678M |
| September 30, 2013 | 4.257M |
| June 30, 2013 | 4.293M |
| March 31, 2013 | 4.292M |
| December 31, 2012 | 4.516M |
| September 30, 2012 | 4.817M |
| June 30, 2012 | 4.299M |
| March 31, 2012 | 3.875M |
| December 31, 2011 | 3.986M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
4.651M
Minimum
Mar 2023
7.168M
Maximum
Mar 2024
5.786M
Average
5.876M
Median
Research and Development Expense (TTM) Benchmarks
| EyePoint Pharmaceuticals Inc | 81.18M |
| Enanta Pharmaceuticals Inc | 151.11M |
| GlycoMimetics Inc | 20.68M |
| FibroGen Inc | 246.77M |
| Corvus Pharmaceuticals Inc | 16.01M |